FDA advisors back Cidara antifungal rezafungin

  26 January 2023

An FDA advisory committee has recommended approval of Cidara Therapeutics’ once-weekly antifungal therapy rezafungin, setting it up to become the first new option for severe infections caused by Candida species in a decade.

The panel voted 14 to 1 that the benefits of Cidara and Melinta Therapeutics’ once-weekly echinocandin drug outweighed its risks as a first-line treatment for candidemia and invasive candidiasis in adults who have limited or no alternative treatment options.

The decision puts Cidara and Melinta on course for a positive outcome when the FDA delivers its verdict on the filing, which is due by 22 March. If approved it will be sold by Melinta, which licensed US rights to it last July and already markets a range of antibacterial drugs.

Further reading: Pharmaphorum
Author(s): Phil Taylor
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 550 AMR professionals and students in 60 countries!

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!
Popup Plugin